TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| UPMC posts $7.7 billion operating revenue Despite a tough economy, operating revenue at the University of Pittsburgh Medical Center rose $653 million to $7.7 billion during the 12-month period ending June 30, for an operating margin of 2.8 percent, up from 2.6 percent for the same period in 2008, according to unaudited results released Friday. feeds.bizjournals.com |
Talecris's Upcoming IPO: I'll Pass Complete Story » seekingalpha.com |
Philips New Sleep Therapy System - Video PHILIPS UNVEILS INTELLIGENT SLEEP APNEA THERAPY SYSTEM TO HOME HEALTHCARE INDUSTRY feedproxy.google.com |
Sen. Reid Weighs Rise in Medicare Tax Senate Majority Leader Harry Reid is considering a proposal to raise Medicare payroll taxes on couples who make more than $250,000 a year. online.barrons.com |
NeoStem: Start of a New Era Mike Havrilla submits:NeoStem (AMEX: NBS) [click on preceding link for the company’s news room website] is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of regenerative medicine and other stem cell applicatons. In late October, NeoStem completed its acquisition of China Biopharmaceuticals, which resulted in a controlling 51% interest in Suzhou Erye Pharmaceuticals (Erye) and established three business segments for the company (US + China stem cells and China pharmaceuticals focused on antibiotics and active pharmaceutical ingredients). NeoStem (US) includes an exclusive worldwide license to VSELs, a strong IP sourcing network for innovative stem cell / pharmaceutical products and AMEX listing for the stock in addition to its position in the domestic market as a leading adult stem cell banking network.Erye is a high-growth pharmaceutical manufacturer in China with a strong core business / profitable revenue base amidst booming demand and growth in the Chinese market.NeoStem (China) has strong support from the Chinese government for commercialization of cosmetic / regenerative medicine applications which will also expedite the process of US development as the company becomes a vertically integrated stem cell operation in a permissive regulatory environment that includes strong government support. NeoStem plans to leverage the R&D conducted in China to fast-track the U.S. FDA approval process. Erye is a China-based pharmaceutical company that is expected to record revenue exceeding US$60 million in 2009. Since closing the merger, the market cap of NeoStem has more than tripled to about $60 million, which reflects additional shares of common stock issued as part of the merger and also approximates the projected revenue for Erye during 2009. Erye is a vertically integrated bio-pharmaceutical company in China focused on intermediate API / antibiotics which also includes a R&D team focused on drug discovery, improving existing drugs, and traditional Chinese medicine products plus a strong distribution network covering 30 provinces in China. The company currently has 7 SFDA approved / certified production lines that are compliant with China GMP standards and is also in the process of a three-year expansion / relocation program that is expected to be completed by 2011.Complete Story » seekingalpha.com |